Condition
Acute Myeloid Leukemia (AML) in Remission
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (2)
Trial Status
Recruiting4
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07521124Not ApplicableNot Yet RecruitingPrimary
ABC Maintenance Therapy for AML
NCT04990102Phase 1RecruitingPrimary
Phase IB/II of CPX-351 for Relapse Prevention in AML
NCT04314219Phase 3Recruiting
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
NCT05477589Phase 3RecruitingPrimary
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
NCT05404906Phase 2RecruitingPrimary
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Showing all 5 trials